Gordon Ralph Corey, MD

Professor of Medicine
Gary Hock Professor in Global Health, in the School of Medicine
Vice-Chair for Education and Global Health in the Department of Medicine
Research Professor of Global Health
Professor of Pathology
Member in the Duke Clinical Research Institute
Campus mail 310 Trent Drive Room 235 Trent, Box 90519, Durham, NC 27708
Phone (919) 668-7174
Email address corey001@mc.duke.edu

My research is based at the Duke Clinical Research Institute, a large academic clinical research organization designed to conduct clinical trials from small local studies to worldwide trials. The focus of my research is bacterial infections: complicated skin and skin structure infections; postoperative wound infections; hospital-acquired and ventilator-associated pneumonia; bacteremia; and endocarditis. Many of these trials are conducted in concert with the pharmaceutical industry in order to register new antibiotics. In addition, as director of infectious diseases at the DCRI I oversee the work of the mycology group, and tuberculosis trials. This work also includes work supported by NIH grants including sepsis trials, the Staph Aureus and Staph Epi Bacteremia Groups, and the International Collaboration of Endocarditis. The team of investigators with whom I work is highly experienced, amazingly productive and wonderfully collegial.

As a result of my longstanding interest in tropical medicine and the generosity of my patients as well as the Hubert Family we have been able to establish the Hubert-Yeargan Center for Global Health. As a result we have developed a medical center-wide fellowship in Global Health. I am presently the Director of the Center and the Gary Hock Distinguished Professor of Global Health.

Education and Training

  • Fellowship, Infectious Diseases, Duke University School of Medicine, 1978 - 1980
  • Chief Resident, General Internal Medicine, Duke University School of Medicine, 1977 - 1978
  • Residency, General Internal Medicine, Duke University School of Medicine, 1975 - 1977
  • Internship, General Internal Medicine, Duke University School of Medicine, 1974 - 1975
  • M.D., Baylor University, 1973

Publications

Rubinstein, Ethan, G Ralph Corey, Martin E. Stryjewski, and Zeina A. Kanafani. “Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia..” Expert Opin Pharmacother 12, no. 17 (December 2011): 2737–50. https://doi.org/10.1517/14656566.2011.633511.

PMID
22077833
Full Text

Nienaber, Juhsien J. C., Batu K. Sharma Kuinkel, Michael Clarke-Pearson, Supaporn Lamlertthon, Lawrence Park, Thomas H. Rude, Steve Barriere, et al. “Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins..” J Infect Dis 204, no. 5 (September 1, 2011): 704–13. https://doi.org/10.1093/infdis/jir389.

PMID
21844296
Full Text

Moellering, Robert C., G Ralph Corey, and M Lindsay Grayson. “Introduction: fusidic acid enters the United States..” Clin Infect Dis 52 Suppl 7 (June 2011): S467–68. https://doi.org/10.1093/cid/cir171.

PMID
21546622
Full Text

Craft, J Carl, Susan R. Moriarty, Kay Clark, Drusilla Scott, Thorsten P. Degenhardt, J Gordon Still, G Ralph Corey, Anita Das, and Prabhavathi Fernandes. “A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections..” Clin Infect Dis 52 Suppl 7 (June 2011): S520–26. https://doi.org/10.1093/cid/cir167.

PMID
21546629
Full Text

Corey, G Ralph, and Martin E. Stryjewski. “New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good..” Clin Infect Dis 52 Suppl 7 (June 2011): S469–76. https://doi.org/10.1093/cid/cir162.

PMID
21546623
Full Text

Pages